{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:31:37Z","timestamp":1790767897389,"version":"4.1.0"},"reference-count":313,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T00:00:00Z","timestamp":1583884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Vet. Sci."],"DOI":"10.3389\/fvets.2020.00080","type":"journal-article","created":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T04:29:17Z","timestamp":1583900957000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Canine Models of Inherited Musculoskeletal and Neurodegenerative Diseases"],"prefix":"10.3389","volume":"7","author":[{"given":"Brett D.","family":"Story","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew E.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison M.","family":"Bradbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily D.","family":"Million","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toloo","family":"Taghian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Faissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Fernau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidney J.","family":"Beecy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather L.","family":"Gray-Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,3,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/ilar.50.2.112","article-title":"Gene therapy for lysosomal storage diseases (LSDs) in large animal models","volume":"50","author":"Haskins","year":"2009","journal-title":"ILAR J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e91172","DOI":"10.1371\/journal.pone.0091172","article-title":"An improved canine genome and a comprehensive catalogue of coding genes and non-coding transcripts","volume":"9","author":"Hoeppner","year":"2014","journal-title":"PLoS ONE."},{"key":"B3","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1191\/0960327102ht286oa","article-title":"Overview of immune system development in the dog: comparison with humans","volume":"21","author":"Felsburg","year":"2002","journal-title":"Hum Exp Toxicol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2589276","DOI":"10.1155\/2016\/2589276","article-title":"Therapies for prevention and treatment of Alzheimer's disease","volume":"2016","author":"Mendiola-Precoma","year":"2016","journal-title":"BioMed Res Int"},{"key":"B5","article-title":"Alzheimer Disease","volume-title":"StatPearls [Internet].","author":"Kumar","year":"2019"},{"key":"B6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.31887\/DCNS.2000.2.2\/asschachter","article-title":"Alzheimer's disease","volume":"2","author":"Schachter","year":"2000","journal-title":"Dialogues Clin Neurosci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1001\/jama.1997.03550160083043","article-title":"Diagnosis and treatment of Alzheimer disease and related disorders: Consensus Statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society","volume":"278","author":"Small","year":"1997","journal-title":"JAMA"},{"key":"B8","doi-asserted-by":"publisher","first-page":"282","DOI":"10.14336\/AD.2014.002","article-title":"Metabolic risk factors of sporadic Alzheimer's disease: implications in the pathology, pathogenesis and treatment","volume":"6","author":"Chakrabarti","year":"2015","journal-title":"Aging Dis"},{"key":"B9","first-page":"1","article-title":"Early-onset familial Alzheimer disease","volume-title":"GeneReviews","author":"Bird","year":"2012"},{"key":"B10","first-page":"228","article-title":"Alzheimer's disease: early diagnosis and treatment","volume":"18","author":"Chu","year":"2012","journal-title":"Hong Kong Med J"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2015.00221","article-title":"\u03b2-Amyloid: the key peptide in the pathogenesis of Alzheimer's disease","volume":"6","author":"Sun","year":"2015","journal-title":"Front Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"254954","DOI":"10.1155\/2013\/254954","article-title":"Genetics of Alzheimer's disease","volume":"2013","author":"Ridge","year":"2013","journal-title":"BioMed Res Int"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1042\/BST20140164","article-title":"Hypercholesterolaemia-induced oxidative stress at the blood-brain barrier","volume":"42","author":"Dias","year":"2014","journal-title":"Biochem Soc Trans"},{"key":"B14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.cca.2016.02.024","article-title":"Imbalanced cholesterol metabolism in Alzheimer's disease","volume":"456","author":"Xue-Shan","year":"2016","journal-title":"Clin Chim Acta"},{"key":"B15","doi-asserted-by":"publisher","first-page":"105828","DOI":"10.1155\/2015\/105828","article-title":"Inflammation and oxidative stress: the molecular connectivity between insulin resistance, obesity, and Alzheimer's disease","volume":"2015","author":"Verdile","year":"2015","journal-title":"Mediat Inflamm"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-014-0130-5","article-title":"Cardiovascular risk factors and future risk of Alzheimer's disease","volume":"12","author":"de Bruijn","year":"2014","journal-title":"BMC Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/j.bbadis.2014.06.010","article-title":"Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain","volume":"1842","author":"Butterfield","year":"2014","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.4239\/wjd.v6.i12.1223","article-title":"Molecular and biochemical trajectories from diabetes to Alzheimer's disease?: a critical appraisal","volume":"6","author":"Sandhir","year":"2015","journal-title":"World J Diabetes"},{"key":"B19","doi-asserted-by":"publisher","first-page":"7332","DOI":"10.3390\/nu7095341","article-title":"Shared neuropathological characteristics of obesity, type 2 diabetes and Alzheimer's disease: impacts on cognitive decline","volume":"7","author":"Walker","year":"2015","journal-title":"Nutrients"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1001\/jama.276.21.1725","article-title":"A family intervention to delay nursing home placement of patients with Alzheimer's disease: a randomized controlled trial","volume":"276","author":"Mittleman","year":"1996","journal-title":"JAMA"},{"key":"B21","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1001\/jama.277.10.806","article-title":"Predicting time to nursing home care and death in individuals with Alzheimer's disease","volume":"277","author":"Stern","year":"1997","journal-title":"JAMA"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.3390\/molecules23082033","article-title":"Synthesis and Biological Evaluation of New Cholinesterase Inhibitors for Alzheimer's Disease","volume":"23","author":"Hussein","year":"2018","journal-title":"Molecules"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.2174\/1389200219666180813144834","article-title":"Probiotic supplementation in patients with Alzheimer's dementia - an explorative intervention study","volume":"15","author":"Leblhuber","year":"2018","journal-title":"Curr Alzheimer Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1111\/cns.13035","article-title":"A review of clinical treatment considerations of donepezil in severe Alzheimer's disease","volume":"24","author":"Adlimoghaddam","year":"2018","journal-title":"CNS Neurosci Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.applanim.2006.11.007","article-title":"Canine cognitive dysfunction syndrome: prevalence, clinical signs and treatment with a neuroprotective nutraceutical","volume":"105","author":"Osella","year":"2007","journal-title":"Appl Anim Behav Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1748-5827.2008.00718.x","article-title":"Prevalence and risk factors of behavioural changes associated with age-related cognitive impairment in geriatric dogs","volume":"50","author":"Azkona","year":"2009","journal-title":"J Small Anim Pract."},{"key":"B27","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.tvjl.2009.11.007","article-title":"Under diagnosis of canine cognitive dysfunction: A cross-sectional survey of older companion dogs","volume":"184","author":"Salvin","year":"2010","journal-title":"Vet J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.2460\/javma.2001.218.1787","article-title":"Prevalence of behavioral changes associated with age-related cognitive impairment in dogs","volume":"218","author":"Neilson","year":"2001","journal-title":"J Am Vet Med Assoc."},{"key":"B29","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/0169-328X(91)90088-F","article-title":"Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis","volume":"10","author":"Johnstone","year":"1991","journal-title":"Brain Res Mol Brain Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.neuroscience.2010.09.042","article-title":"Cloning, sequencing and expression in the dog of the main amyloid precursor protein isoforms and some of the enzymes related with their processing","volume":"171","author":"Sarasa","year":"2010","journal-title":"Neuroscience."},{"key":"B31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1006\/nlme.1996.0039","article-title":"B-Amyloid accumulation correlates with cognitive dysfunction in the aged canine","volume":"66","author":"Cummings","year":"1996","journal-title":"Neurobiol Learn Mem"},{"key":"B32","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0197-4580(00)00113-5","article-title":"Vascular and parenchymal beta-amyloid deposition in the aging dog: correlation with behavior","volume":"21","author":"Colle","year":"2000","journal-title":"Neurobiol Aging"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jama.283.12.1571","article-title":"Correlation between elevated levels of amyloid \u03b2-peptide in the brain and cognitive decline","volume":"283","author":"Naslund","year":"2000","journal-title":"JAMA"},{"key":"B34","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1354\/vp.36-3-202","article-title":"Age related changes in the brain of the dog","volume":"36","author":"Borras","year":"1999","journal-title":"Vet Pathol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/j.1748-5827.2007.00386.x","article-title":"Cognitive dysfunction and the neurobiology of ageing in cats","volume":"48","author":"Gunn-Moore","year":"2007","journal-title":"J Small Anim Pract"},{"key":"B36","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jfms.2006.01.003","article-title":"Ageing changes in cat brains demonstrated by beta-amyloid and AT8-immunoreactive phosphorylated tau deposits","volume":"8","author":"Gunn-Moore","year":"2006","journal-title":"J Feline Med Surg"},{"key":"B37","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.neurobiolaging.2004.06.015","article-title":"Beta-amyloid deposition and tau phosphorylation in clinically characterized aged cats","volume":"26","author":"Head","year":"2005","journal-title":"Neurobiol Aging"},{"key":"B38","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.cvsm.2012.04.003","article-title":"Cognitive Dysfunction Syndrome","volume":"42","author":"Landsberg","year":"2012","journal-title":"Vet Clin N Am Small Anim Pract"},{"key":"B39","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1111\/jvim.12109","article-title":"An observational study with long-term follow-up of canine cognitive dysfunction: clinical characteristics, survival, and risk factors","volume":"27","author":"Fast","year":"2013","journal-title":"J Vet Int Med"},{"key":"B40","first-page":"415","article-title":"The effects of aging on the behavior of senior pets","volume-title":"Handbook of Behavior Problems of the Dog and Cat","author":"Landsberg","year":"2003"},{"key":"B41","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/j.1740-8261.2005.00083.x","article-title":"Measurement of interthalamic adhesion thickness as a criteria for brain atrophy in dogs with and without cognitive dysfunction (dementia)","volume":"46","author":"Hasegawa","year":"2005","journal-title":"Vet Radiol Ultrasound"},{"key":"B42","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/vru.12528","article-title":"Evaluation of interthalamic adhesion size as an indicator of brain atrophy in dogs with and without cognitive dysfunction","volume":"58","author":"Noh","year":"2017","journal-title":"Vet Radiol Ultrasound."},{"key":"B43","article-title":"Effects of an investigational food on age-related behavioral changes in dogs","volume-title":"Proceedings of the Symposium on Brain Aging and Related Behavioral Changes in Dogs","author":"Jewell","year":"2002"},{"key":"B44","first-page":"31","article-title":"The effects of antioxidant-fortified food and cognitive enrichment in dogs","volume":"97","author":"Milgram","year":"2002","journal-title":"Vet Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1007\/s11064-008-9808-4","article-title":"Oxidative damage and cognitive dysfunction: antioxidant treatments to promote healthy brain aging","volume":"34","author":"Head","year":"2009","journal-title":"Neurochem Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0149-7634(02)00039-8","article-title":"Landmark discrimination learning in aged dogs is improved by treatment with an antioxidant diet","volume":"26","author":"Milgram","year":"2000","journal-title":"Soc Neurosci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S0197-4580(02)00073-8","article-title":"Brain aging in the canine: a diet enriched in antioxidants reduces cognitive dysfunction","volume":"23","author":"Cotman","year":"2002","journal-title":"Neurobiol Aging"},{"key":"B48","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3389\/fnut.2018.00127","article-title":"Efficacy of a Therapeutic Diet on Dogs With Signs of Cognitive Dysfunction Syndrome (CDS): A Prospective Double Blinded Placebo Controlled Clinical Study","volume":"5","author":"Pan","year":"2018","journal-title":"Front Nutr."},{"key":"B49","first-page":"24","article-title":"A noncomparative open-label study evaluating the effect of selegiline hydrochloride in a clinical setting","volume":"2","author":"Campbell","year":"2001","journal-title":"Vet Ther"},{"key":"B50","first-page":"69","article-title":"Effect of S-adenosylmethionine tablets on the reduction of age-related mental decline in dogs: a double-blinded, placebo-controlled trial","volume":"9","author":"Reme","year":"2008","journal-title":"Vet Ther"},{"key":"B51","doi-asserted-by":"publisher","first-page":"407","DOI":"10.5326\/0420407","article-title":"Therapeutic options for cognitive decline in senior pets","volume":"42","author":"Landsberg","year":"2006","journal-title":"J Am Anim Hosp Assoc"},{"key":"B52","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.pnpbp.2004.12.012","article-title":"Therapeutic agents for the treatment of cognitive dysfunction syndrome in senior dogs","volume":"29","author":"Landsberg","year":"2005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B53","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.cvsm.2019.01.013","article-title":"Canine cognitive dysfunction: pathophysiology, diagnosis, and treatment","volume":"49","author":"Dewey","year":"2019","journal-title":"Vet Clin N Am Small Anim Pract."},{"key":"B54","first-page":"317","article-title":"New pharmacologic aspects in the neurologic profile of propentofylline (Karsivan ad us. vet.)","volume":"26","author":"Kapl","year":"1998","journal-title":"Tierarztl Prax Ausg K Klientiere Heimtiere"},{"key":"B55","first-page":"5","article-title":"Prior experience, antioxidants, mitochondrial cofactors improve cognitive function in aged Beagles","volume":"5","author":"Ikeda-Douglas","year":"2004","journal-title":"Vet Ther"},{"key":"B56","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4103\/2152-7806.169561","article-title":"A comprehensive review of amyotrophic lateral sclerosis","volume":"6","author":"Zarei","year":"2015","journal-title":"Surg Neurol Int"},{"key":"B57","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1056\/NEJMra1603471","article-title":"Amyotrophic Lateral Sclerosis","volume":"377","author":"Brown","year":"2017","journal-title":"New Engl J Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000108917","article-title":"Amyotrophic lateral sclerosis in South-East England: A population-based study","volume":"29","author":"Abhinav","year":"2007","journal-title":"Neuroepidemiology"},{"key":"B59","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/ng1742","article-title":"ANG mutations segregate with familial and \u2018sporadic' amyotrophic lateral sclerosis","volume":"38","author":"Greenway","year":"2006","journal-title":"Nat Genet"},{"key":"B60","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/ajmg.b.31158","article-title":"Mutational analysis reveals the FUS homolog TAF15 as a candidate gene for familial amyotrophic lateral sclerosis","author":"Ticozzi","year":"2011","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"B61","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1212\/01.wnl.0000296811.19811.db","article-title":"Genetics of familial amyotrophic lateral sclerosis","volume":"70","author":"Valdmanis","year":"2008","journal-title":"Neurology"},{"key":"B62","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/(SICI)1097-4598(200003)23:3<336::AID-MUS4>3.0.CO;2-L","article-title":"Amyotrophic lateral sclerosis: early contributions of Jean-Martin Charcot","volume":"23","author":"Goetz","year":"2000","journal-title":"Muscle Nerve"},{"key":"B63","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1750-1172-4-3","article-title":"Amyotrophic lateral sclerosis","volume":"4","author":"Wijesekera","year":"2009","journal-title":"Orphanet J Rare Dis"},{"key":"B64","doi-asserted-by":"publisher","first-page":"iv32","DOI":"10.1136\/jnnp.74.suppl_4.iv32","article-title":"The management of motor neuron disease","volume":"74","author":"Leigh","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B65","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1136\/jnnp.66.1.5","article-title":"Respiratory aspects of neurological disease","volume":"66","author":"Polkey","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B66","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1136\/jnnp.2008.156976","article-title":"Prospective study of chemical exposures and amyotrophic lateral sclerosis","volume":"80","author":"Weisskopf","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B67","doi-asserted-by":"publisher","first-page":"254680","DOI":"10.1155\/2014\/254680","article-title":"Pu-erh tea extract induces the degradation of FET family proteins involved in the pathogenesis of amyotrophic lateral sclerosis","volume":"2014","author":"Yu","year":"2014","journal-title":"Biomed Res Int"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1093\/oxfordjournals.aje.a009070","article-title":"Occupational exposures and amyotrophic lateral sclerosis. A population-based case-control study","volume":"145","author":"McGuire","year":"1997","journal-title":"Am J Epidemiol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.neuro.2016.06.015","article-title":"Identification of risk factors associated with onset and progression of amyotrophic lateral sclerosis using systematic review and meta-analysis","volume":"61","author":"Wang","year":"2016","journal-title":"Neuro Toxicol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1136\/jnnp.2010.224501","article-title":"Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis","volume":"82","author":"Byrne","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1242\/bio.201410066","article-title":"A genetic screen identifies Tor as an interactor of VAPB in a Drosophila model of amyotrophic lateral sclerosis","volume":"3","author":"Deivasigamani","year":"2014","journal-title":"Biol Open"},{"key":"B72","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1177\/1073858414555404","article-title":"Amyotrophic lateral sclerosis genetic studies: from genome-wide association mapping to genome sequencing","volume":"21","author":"He","year":"2015","journal-title":"Neuroscientist"},{"key":"B73","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/S0140-6736(10)61156-7","article-title":"Amyotrophic lateral sclerosis","volume":"377","author":"Kiernan","year":"2011","journal-title":"Lancet"},{"key":"B74","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.brainres.2012.02.059","article-title":"Misregulated RNA processing in amyotrophic lateral sclerosis","volume":"1462","author":"Polymenidou","year":"2012","journal-title":"Brain Res"},{"key":"B75","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1523\/JNEUROSCI.4385-04.2005","article-title":"Mutant superoxide dismutase 1 forms aggregates in the brain mitochondrial matrix of amyotrophic lateral sclerosis mice","volume":"25","author":"Vijayvergiya","year":"2005","journal-title":"J Neurosci"},{"key":"B76","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/362059a0","article-title":"Mutations in Cu\/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis","volume":"362","author":"Rosen","year":"1993","journal-title":"Nature"},{"key":"B77","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1136\/jnnp.2009.194399","article-title":"FUS mutations in amyotrophic lateral sclerosis: Clinical, pathological, neurophysiological and genetic analysis","volume":"81","author":"Blair","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B78","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1136\/jmg.2009.071027","article-title":"Mutations of FUS gene in sporadic amyotrophic lateral sclerosis","volume":"47","author":"Corrado","year":"2010","journal-title":"J Med Genet"},{"key":"B79","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/S1474-4422(11)70261-7","article-title":"C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study","volume":"11","author":"Gijselinck","year":"2012","journal-title":"Lancet Neurol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"e1002214","DOI":"10.1371\/journal.pgen.1002214","article-title":"FUS and TARDBP but not SOD1 interact in genetic models of amyotrophic lateral sclerosis","volume":"7","author":"Kabashi","year":"2011","journal-title":"PLoS Genet"},{"key":"B81","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.yneu.2012.05.040","article-title":"Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study","volume":"11","author":"Majounie","year":"2012","journal-title":"Lancet Neurol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1001\/archneurol.2010.352","article-title":"Large proportion of amyotrophic lateral sclerosis cases in Sardinia due to a single founder mutation of the TARDBP gene","volume":"68","author":"Chi\u00f2","year":"2011","journal-title":"Arch Neurol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1126\/science.1166066","article-title":"Mutations in the FUS\/TLS Gene on Chromosome 16 Cause Familial Amyotrophic Lateral Sclerosis","volume":"323","author":"Kwiatkowski","year":"2009","journal-title":"Science"},{"key":"B84","first-page":"735","article-title":"An Iranian familial amyotrophic lateral sclerosis pedigree with p.Val48Phe causing mutation in SOD1, a genetic and clinical report","volume":"17","author":"Alavi","year":"2014","journal-title":"Iran. J. Basic Med. Sci"},{"key":"B85","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/nn.3357","article-title":"Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis","volume":"16","author":"Kang","year":"2013","journal-title":"Nat Neuro sci."},{"key":"B86","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.expneurol.2014.05.015","article-title":"Glial cells in amyotrophic lateral sclerosis","volume":"262","author":"Phillips","year":"2014","journal-title":"Exp Neurol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"17085","DOI":"10.1038\/nrdp.2017.85","article-title":"Amyotrophic lateral sclerosis","volume":"3","author":"Hardiman","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B88","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/j.1468-1331.2011.03501.x","article-title":"EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS) \u2013 Revised report of an EFNS task force","volume":"19","author":"Andersen","year":"2012","journal-title":"Eur. J. Neurol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.clinph.2007.09.143","article-title":"Electrodiagnostic criteria for diagnosis of ALS","volume":"119","author":"de Carvalho","year":"2008","journal-title":"Clin Neurophysiol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nrneurol.2011.153","article-title":"Clinical diagnosis and management of amyotrophic lateral sclerosis","volume":"7","author":"Hardiman","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/17482960701656940","article-title":"Causes of death in a post-mortem series of ALS patients","volume":"9","author":"Corcia","year":"2008","journal-title":"Amyotroph Lateral Scler"},{"key":"B92","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.cvsm.2010.05.001","article-title":"Canine degenerative myelopathy","volume":"40","author":"Coates","year":"2010","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"B93","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1073\/pnas.0812297106","article-title":"Genome-wide association analysis reveals a SOD1 mutation in canine degenerative myelopathy that resembles amyotrophic lateral sclerosis","volume":"106","author":"Tomoyuki","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"B94","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1354\/vp.08-VP-0270-M-BC","article-title":"Degenerative myelopathy in two Boxer dogs","volume":"46","author":"Miller","year":"2009","journal-title":"Vet. Pathol"},{"key":"B95","volume-title":"Veterinary Neuroanatomy and Clinical Neurology","author":"de Lahunta","year":"2009"},{"key":"B96","first-page":"414","article-title":"Differential diagnosis of progressive caudal paresis in an aged German Shepherd dog","volume":"11","author":"Kneller","year":"1975","journal-title":"J Am Anim Hosp Assoc"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1111\/j.1939-1676.2007.tb01955.x","article-title":"Clinical characterization of a familial degenerative myelopathy in Pembroke Welsh Corgi dogs","volume":"21","author":"Coates","year":"2007","journal-title":"J Vet Intern Med."},{"key":"B98","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/j.1939-1676.2006.tb01807.x","article-title":"Daily controlled physiotherapy increases survival time in dogs with suspected degenerative myelopathy","volume":"20","author":"Kathmann","year":"2006","journal-title":"J Vet Intern Med"},{"key":"B99","author":"Faissler","year":"2019","journal-title":"Adeno-Associated Virus Mediated SOD1 Gene Silencing Therapy in Naturally Occurring Canine Degenerative Myelopathy"},{"key":"B100","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1177\/2192568218758633","article-title":"The role of vitamin B12 in the management and optimization of treatment in patients with degenerative cervical myelopathy","volume":"9","author":"Nouri","year":"2018","journal-title":"Global Spine J"},{"key":"B101","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/WNR.0000000000001151","article-title":"Protein disulphide isomerase is associated with mutant SOD1 in canine degenerative myelopathy","volume":"30","author":"Chang","year":"2019","journal-title":"Neuroreport"},{"key":"B102","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.3390\/ijms20184388","article-title":"Gene therapy for ALS\u2014a perspective","volume":"20","author":"Cappella","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B103","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.neulet.2018.09.040","article-title":"Activation of the unfolded protein response in canine degenerative myelopathy","volume":"687","author":"Yokota","year":"2018","journal-title":"Neurosci Lett"},{"key":"B104","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.bbadis.2006.06.010","article-title":"The neuronal ceroid-lipofuscinoses: from past to present","volume":"1762","author":"Haltia","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"B105","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/ajmg.1320310606","article-title":"Batten disease: past, present, and future","volume":"5","author":"Rider","year":"1988","journal-title":"Am J Med Genet."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1016\/j.bbadis.2013.04.008","article-title":"NCL diseases - clinical perspectives","volume":"11","author":"Schulz","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/j.bbadis.2012.08.012","article-title":"The neuronal ceroid-lipofuscinoses: a historical introduction","volume":"1832","author":"Haltia","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"B108","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1016\/j.bbadis.2015.05.007","article-title":"Human NCL neuropathology","volume":"1852","author":"Radke","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"B109","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/gt.2017.4","article-title":"Extraneuronal pathology in a canine model of CLN2 neuronal ceroid lipofuscinosis after intracerebroventricular gene therapy that delays neurological disease progression","volume":"24","author":"Katz","year":"2017","journal-title":"Gene Ther."},{"key":"B110","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.ymgme.2005.11.005","article-title":"A mutation in the cathepsin D gene (CTSD) in American Bulldogs with neuronal ceroid lipofuscinosis","volume":"87","author":"Tomoyuki","year":"2006","journal-title":"Mol Genet Metab."},{"key":"B111","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/ajmg.1320570219","article-title":"Morphological alterations in neocortical and cerebellar GABAergic neurons in a canine model of juvenile Batten disease","volume":"57","author":"March","year":"1995","journal-title":"Am J Med Genet."},{"key":"B112","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/ajmg.1320310616","article-title":"The English setter with ceroid-lipofuscinosis: a suitable model for the juvenile type of ceroid-lipofuscinosis in humans","volume":"31","author":"Koppang","year":"1988","journal-title":"Am J Med Genet."},{"key":"B113","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.bbrc.2004.12.038","article-title":"A mutation in the CLN8 gene in English Setter dogs with neuronal ceroid-lipofuscinosis","volume":"327","author":"Katz","year":"2005","journal-title":"Biochem Biophys Res Commun."},{"key":"B114","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ygeno.2005.06.005","article-title":"A mutation in canine CLN5 causes neuronal ceroid lipofuscinosis in Border collie dogs","volume":"86","author":"Melville","year":"2005","journal-title":"Genomics."},{"key":"B115","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ymgme.2018.11.015","article-title":"ATP13A2 missense variant in Australian Cattle Dogs with late onset neuronal ceroid lipofuscinosis","volume":"127","author":"Schmutz","year":"2019","journal-title":"Mol Genet Metab."},{"key":"B116","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1016\/j.bbadis.2015.05.011","article-title":"Genetics of the neuronal ceroid lipofuscinoses (Batten disease)","volume":"1852","author":"Mole","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"B117","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.nbd.2017.08.017","article-title":"Canine neuronal ceroid lipofuscinoses: Promising models for preclinical testing of therapeutic interventions","volume":"108","author":"Katz","year":"2018","journal-title":"Neurobiol Dis"},{"key":"B118","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0047-6374(73)90034-1","article-title":"Canine ceroid-lipofuscinosis-a model for human neuronal ceroid-lipofuscinosis and aging","volume":"2","author":"Koppang","year":"1974","journal-title":"Mech Ageing Dev"},{"key":"B119","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/j.1399-0004.1990.tb04188.x","article-title":"Batten's disease: Failure of allogeneic bone marrow transplantation to arrest disease progression in a canine model","volume":"37","author":"Deeg","year":"1990","journal-title":"Clin Genet."},{"key":"B120","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1053\/ejpn.2000.0453","article-title":"Assessment of dietary therapies in a canine model of Batten disease","volume":"5","author":"Siakotos","year":"2001","journal-title":"Euro J Paediatr Neurol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.ymgme.2011.06.018","article-title":"Intrathecal tripeptidyl-peptidase 1 reduces lysosomal storage in a canine model of late infantile neuronal ceroid lipofuscinosis","volume":"104","author":"Vuillemenot","year":"2011","journal-title":"Mol Genet Metab."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/jnr.23423","article-title":"Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease)","volume":"92","author":"Katz","year":"2014","journal-title":"J Neurosci Res."},{"key":"B123","doi-asserted-by":"publisher","first-page":"313ra180","DOI":"10.1126\/scitranslmed.aac6191","article-title":"AAV gene transfer delays disease onset in a TPP1-deficient canine model of the late infantile form of Batten disease","volume":"7","author":"Katz","year":"2015","journal-title":"Sci Transl Med."},{"key":"B124","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40263-019-00620-8","article-title":"Current and emerging treatment strategies for neuronal ceroid lipofuscinoses","volume":"33","author":"Kohlsch\u00fctter","year":"2019","journal-title":"CNS Drugs."},{"key":"B125","first-page":"2","article-title":"Krabbe disease locus mapped to chromosome 14 by genetic linkage","volume":"555","author":"Zoglotora","year":"2015","journal-title":"Am J Hum Genet"},{"key":"B126","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1136\/jnnp.26.3.195","article-title":"Diagnosis of Krabbe's infantile leukodystrophy","volume":"26","author":"Hagberg","year":"1963","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B127","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1055\/s-0028-1091865","article-title":"Infantile globoid cell leukodystrophy (Krabbe's disease). A clinical and genetic study of 32 Swedish cases 1953\u20131967","volume":"1","author":"Hagberg","year":"1969","journal-title":"Neuropadiatrie"},{"key":"B128","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1177\/08830738030180090201","article-title":"Globoid cell leukodystrophy (Krabbe's disease): update","volume":"18","author":"Suzuki","year":"2003","journal-title":"J. Child Neurol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2183\/pjab.79B.1","article-title":"Evolving perspective of the pathogenesis of globoid cell leukodystrophy (Krabbe disease)","volume":"79","author":"Suzuki","year":"2003","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"B130","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1126\/science.6719111","article-title":"Progressive accumulation of toxic metabolite in a genetic leukodystrophy","volume":"224","author":"Igisu","year":"1984","journal-title":"Science."},{"key":"B131","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/0006-8993(80)90159-6","article-title":"The twitcher mouse: an enzymatically authentic model of human globoid cell leukodystrophy (Krabbe disease)","volume":"202","author":"Kobayashi","year":"1980","journal-title":"Brain Res"},{"key":"B132","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0022-2275(20)39839-4","article-title":"Krabbe disease: a galactosylsphingosine (psychosine) lipidosis","volume":"21","author":"Svennerholm","year":"1980","journal-title":"J Lipid Res"},{"key":"B133","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/0006-291X(72)90381-6","article-title":"Globoid cell leukodystrophy: additional deficiency of psychosine galactosidase","volume":"48","author":"Miyatake","year":"1972","journal-title":"Biochem Biophys Res Commun."},{"key":"B134","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/978-1-4684-7735-1_8","article-title":"Chemical pathology of Krabbe disease: the occurrence of psychosine and other neutral sphingoglycolipids","volume-title":"Current Trends in Sphingolipidoses and Allied Disorders","author":"Vanier","year":"1976"},{"key":"B135","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/00005072-196504000-00008","article-title":"Studies in globoid (Krabbe) leukodystrophy. III Significance of experimentally-produced globoid-like elements in rat white matter and spleen","volume":"24","author":"Austin","year":"1965","journal-title":"J Neuropathol Exp Neurol."},{"key":"B136","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-1-4684-7735-1_7","article-title":"Studies on the pathogenesis of Krabbe's leukodystrophy: cellular reaction of the brain to exogenous galactosylsphingosine, monogalactosyl diglyceride and lactosylceramide","volume-title":"Current Trends in Sphingolipidoses and Allied Disorders","author":"Suzuki","year":"1976"},{"key":"B137","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1086\/619236","article-title":"Physiological activity of psychosine","volume":"34","author":"Taketomi","year":"1964","journal-title":"Jpn J Exp Med"},{"key":"B138","doi-asserted-by":"crossref","first-page":"5398","DOI":"10.1016\/S0021-9258(20)81118-1","article-title":"Galactosylsphingosine galactosyl hydrolase. Partial purification and properties of the enzyme in the rat brain","volume":"247","author":"Miyatake","year":"1972","journal-title":"J Biol Chem"},{"key":"B139","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.gene.2014.09.046","article-title":"History, genetic, and recent advances on Krabbe disease","volume":"555","author":"Graziano","year":"2015","journal-title":"Gene"},{"key":"B140","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1001\/archneur.1963.00460010098012","article-title":"Krabbe's disease: globoid cell type of leukodystrophy","volume":"8","author":"D'Agostino","year":"1963","journal-title":"Arch Neurol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/BF00689987","article-title":"Fetal Krabbe leukodystrophy: a morphologic study of two cases","volume":"53","author":"Martin","year":"1981","journal-title":"Acta Neuropathol"},{"key":"B142","first-page":"3669","article-title":"Galactosylceramide lipidosis: Globoid cell leukodystrophy (Krabbe disease)","volume-title":"The Metabolic and Molecular Basis of Inherited Disease, 8th edn","author":"Wenger","year":"2001"},{"key":"B143","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1006\/mgme.2000.2990","article-title":"Krabbe disease: genetic aspects and progress toward therapy","volume":"70","author":"Wenger","year":"2000","journal-title":"Mol Genet Metab"},{"key":"B144","first-page":"165","article-title":"Globoid cell leukodystrophy (Krabbe type) in the dog","volume":"149","author":"Fletcher","year":"1966","journal-title":"J Am Vet Med Assoc"},{"key":"B145","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/j.1748-5827.1971.tb06187.x","article-title":"Globoid cell leukodystrophy in two dogs","volume":"12","author":"Howell","year":"1971","journal-title":"J Small Anim Pract"},{"key":"B146","first-page":"380","article-title":"Globoid cell leukodystrophy in a Beagle","volume":"167","author":"Johnson","year":"1975","journal-title":"J Am Vet Med Assoc"},{"key":"B147","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/0014-4886(70)90037-3","article-title":"Studies in globoid leukodystrophy: enzymatic and lipid findings in the canine form","volume":"29","author":"Suzuki","year":"1970","journal-title":"Exp Neurol"},{"key":"B148","first-page":"248","article-title":"Globoid cell leukodystrophy in a miniature Poodle","volume":"163","author":"Zaki","year":"1973","journal-title":"J Am Vet Med Assoc"},{"key":"B149","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/jnr.23838","article-title":"Clinical, electrophysiological, biochemical markers of peripheral and central nervous system disease in canine globoid cell leukodystrophy (Krabbe disease)","volume":"94","author":"Bradbury","year":"2016"},{"key":"B150","doi-asserted-by":"publisher","first-page":"682","DOI":"10.2460\/javma.237.6.682","article-title":"Clinical signs and neuropathologic abnormalities in working Australian Kelpies with globoid cell leukodystrophy (Krabbe disease)","volume":"237","author":"Fletcher","year":"2010","journal-title":"J Am Vet Med Assoc"},{"key":"B151","first-page":"375","article-title":"Animal model: globoid cell leukodystrophy in the dog","volume":"66","author":"Fletcher","year":"1972","journal-title":"Am J Pathol"},{"key":"B152","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1212\/WNL.27.8.758","article-title":"Galactocerebrosidase activity in canine globoid cell leukodystrophy","volume":"27","author":"Fletcher","year":"1977","journal-title":"Neurology"},{"key":"B153","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1093\/jhered\/90.1.138","article-title":"Globoid cell leukodystrophy in cairn and West Highland white terriers","volume":"90","author":"Wenger","year":"1999","journal-title":"J Hered"},{"key":"B154","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1089\/hum.2017.151","article-title":"AAVrh10 Gene Therapy Ameliorates Central and Peripheral Nervous System Disease in Canine Globoid Cell Leukodystrophy (Krabbe Disease)","volume":"29","author":"Bradbury","year":"2018","journal-title":"Hum Gene Ther"},{"key":"B155","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/gim.2016.35","article-title":"Clinical outcomes of children with abnormal newborn screening results for Krabbe disease in New York State","volume":"18","author":"Wasserstein","year":"2016","journal-title":"Genet Med"},{"key":"B156","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.nmd.2013.02.012","article-title":"Early neurodevelopmental assessment in Duchenne muscular dystrophy","volume":"23","author":"Pane","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"B157","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1097\/00005072-199710000-00010","article-title":"Human mucopolysaccharidosis IIID: clinical, biochemical, morphological and immunohistochemical characteristics","volume":"56","author":"Jones","year":"1997","journal-title":"J Neuropathol Exp Neurol"},{"key":"B158","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2006.09.016","article-title":"Pathophysiology of duchenne muscular dystrophy: current hypotheses","volume":"36","author":"Decornick","year":"2007","journal-title":"Pediatr Neurol"},{"key":"B159","doi-asserted-by":"publisher","first-page":"236","DOI":"10.4103\/0028-3886.43441","article-title":"Duchenne muscular dystrophy","volume":"56","author":"Yiu","year":"2008","journal-title":"Neurol India"},{"key":"B160","doi-asserted-by":"publisher","first-page":"18168","DOI":"10.3390\/molecules201018168","article-title":"Duchenne muscular dystrophy: from diagnosis to therapy","volume":"20","author":"Falzarano","year":"2015","journal-title":"Molecules"},{"key":"B161","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/sj.embor.7400221","article-title":"Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment","volume":"5","author":"Nowak","year":"2004","journal-title":"EMBO Rep"},{"key":"B162","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1161\/CIRCRESAHA.107.162982","article-title":"Prevention of dystrophin-deficient cardiomyopathy in twenty-one-month-old carrier mice by mosaic dystrophin expression or complementary dystrophin\/utrophin expression","volume":"102","author":"Bostick","year":"2008","journal-title":"Circ Res."},{"key":"B163","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1242\/dmm.018424","article-title":"Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy","volume":"8","author":"Mcgreevy","year":"2015","journal-title":"Dis Model Mech."},{"key":"B164","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/0022-510X(88)90206-7","article-title":"Canine X-linked muscular dystrophy. An animal model of Duchenne muscular dystrophy: clinical studies","volume":"88","author":"Valentine","year":"1988","journal-title":"J Neurol Sci"},{"key":"B165","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2460\/ajvr.1996.57.05.650","article-title":"Mutation segregation and rapid carrier detection of X-linked muscular dystrophy in dogs","volume":"57","author":"Bartlett","year":"1996","journal-title":"Am J Vet Res."},{"key":"B166","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/labinvest.2010.146","article-title":"An intronic LINE-1 element insertion in the dystrophin gene aborts dystrophin expression and results in Duchenne-like muscular dystrophy in the corgi breed","volume":"91","author":"Smith","year":"2011","journal-title":"Lab Invest."},{"key":"B167","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/mus.20154","article-title":"Effects of prednisone in canine muscular dystrophy","volume":"30","author":"Liu","year":"2004","journal-title":"Muscle Nerve."},{"key":"B168","doi-asserted-by":"publisher","first-page":"e48478","DOI":"10.1371\/journal.pone.0048478","article-title":"Effects of an immunosuppressive treatment in the GRMD dog model of Duchenne muscular dystrophy","volume":"7","author":"Barthelemy","year":"2012","journal-title":"PLoS ONE."},{"key":"B169","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1242\/dmm.012211","article-title":"Levels of alpha7 integrin and laminin-alpha2 are increased following prednisone treatment in the mdx mouse and GRMD dog models of Duchenne muscular dystrophy","volume":"6","author":"Wuebbles","year":"2013","journal-title":"Dis Model Mech."},{"key":"B170","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/2044-5040-4-18","article-title":"NBD delivery improves the disease phenotype of the golden retriever model of Duchenne muscular dystrophy","volume":"4","author":"Kornegay","year":"2014","journal-title":"Skelet Muscle."},{"key":"B171","doi-asserted-by":"publisher","first-page":"e90341","DOI":"10.1172\/jci.insight.90341","article-title":"Disease-modifying effects of orally bioavailable NF-kappaB inhibitors in dystrophin-deficient muscle","volume":"1","author":"Hammers","year":"2016","journal-title":"JCI Insight."},{"key":"B172","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3389\/fphar.2011.00089","article-title":"Chronic administration of a leupeptin-derived calpain inhibitor fails to ameliorate severe muscle pathology in a canine model of duchenne muscular dystrophy","volume":"2","author":"Childers","year":"2011","journal-title":"Front Pharmacol."},{"key":"B173","doi-asserted-by":"publisher","first-page":"e61367","DOI":"10.1371\/journal.pone.0061367","article-title":"Bortezomib (PS-341) treatment decreases inflammation and partially rescues the expression of the dystrophin-glycoprotein complex in GRMD dogs","volume":"8","author":"Araujo","year":"2013","journal-title":"PLoS ONE."},{"key":"B174","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00395-011-0240-6","article-title":"Vascular endothelial dysfunction in Duchenne muscular dystrophy is restored by bradykinin through upregulation of eNOS and nNOS","volume":"105","author":"Dabire","year":"2012","journal-title":"Basic Res Cardiol."},{"key":"B175","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1093\/cvr\/cvs161","article-title":"Bradykinin restores left ventricular function, sarcomeric protein phosphorylation, and e\/nNOS levels in dogs with Duchenne muscular dystrophy cardiomyopathy","volume":"95","author":"Su","year":"2012","journal-title":"Cardiovasc Res."},{"key":"B176","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1093\/hmg\/ddz086","article-title":"Laminin-111 protein therapy enhances muscle regeneration and repair in the GRMD dog model of Duchenne muscular dystrophy","volume":"28","author":"Barraza-Flores","year":"2019","journal-title":"Hum Mol Genet."},{"key":"B177","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/978-1-4684-5865-7_32","article-title":"The role of the xmd dog in the assessment of myoblast transfer therapy","volume":"280","author":"Cooper","year":"1990","journal-title":"Adv Exp Med Biol"},{"key":"B178","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/978-1-4684-5865-7_31","article-title":"Molecular markers for myoblast transplantation in GRMD","volume":"280","author":"Bartlett","year":"1990","journal-title":"Adv Exp Med Biol"},{"key":"B179","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0960-8966(97)00148-X","article-title":"Myoblast transplantation in non-dystrophic dog","volume":"8","author":"Ito","year":"1998","journal-title":"Neuromuscul Disord."},{"key":"B180","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/nature05282","article-title":"Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs","volume":"444","author":"Sampaolesi","year":"2006","journal-title":"Nature"},{"key":"B181","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1479-5876-6-35","article-title":"Early transplantation of human immature dental pulp stem cells from baby teeth to golden retriever muscular dystrophy (GRMD) dogs: Local or systemic?","volume":"6","author":"Kerkis","year":"2008","journal-title":"J Transl Med."},{"key":"B182","doi-asserted-by":"publisher","first-page":"715251","DOI":"10.1155\/2011\/715251","article-title":"Preclinical studies with umbilical cord mesenchymal stromal cells in different animal models for muscular dystrophy","volume":"2011","author":"Zucconi","year":"2011","journal-title":"J Biomed Biotechnol."},{"key":"B183","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1016\/j.ajpath.2011.07.022","article-title":"Systemic delivery of allogenic muscle stem cells induces long-term muscle repair and clinical efficacy in Duchenne muscular dystrophy dogs","volume":"179","author":"Rouger","year":"2011","journal-title":"Am J Pathol."},{"key":"B184","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1177\/0963689718776306","article-title":"Vascular delivery of allogeneic mustem cells in dystrophic dogs requires only short-term immunosuppression to avoid host immunity and generate clinical\/tissue benefits","volume":"27","author":"Lorant","year":"2018","journal-title":"Cell Transplant."},{"key":"B185","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.3727\/096368911X","article-title":"Human adipose-derived mesenchymal stromal cells injected systemically into GRMD dogs without immunosuppression are able to reach the host muscle and express human dystrophin","volume":"21","author":"Vieira","year":"2012","journal-title":"Cell Transplant."},{"key":"B186","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s12015-016-9659-3","article-title":"Transplantation of human adipose mesenchymal stem cells in non-immunosuppressed GRMD dogs is a safe procedure","volume":"12","author":"Pelatti","year":"2016","journal-title":"Stem Cell Rev Rep"},{"key":"B187","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/mt.2016.163","article-title":"Adaptive immune response impairs the efficacy of autologous transplantation of engineered stem cells in dystrophic dogs","volume":"24","author":"Sitzia","year":"2016","journal-title":"Mol Ther."},{"key":"B188","first-page":"86","article-title":"Myodys, a full-length dystrophin plasmid vector for Duchenne and Becker muscular dystrophy gene therapy","volume":"10","author":"Duan","year":"2008","journal-title":"Curr Opin Mol Ther."},{"key":"B189","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/S0960-8966(02)00082-2","article-title":"Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne\/Becker muscular dystrophies. Part I: rationale","volume":"12","author":"Thioudellet","year":"2002","journal-title":"Neuromuscul Disord."},{"key":"B190","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1089\/hum.2004.15.1065","article-title":"Phase I study of dystrophin plasmid-based gene therapy in Duchenne\/Becker muscular dystrophy","volume":"15","author":"Romero","year":"2004","journal-title":"Hum Gene Ther."},{"key":"B191","first-page":"499","article-title":"Naked plasmid DNA for the treatment of muscular dystrophy","volume":"6","author":"Braun","year":"2004","journal-title":"Curr Opin Mol Ther."},{"key":"B192","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1089\/hum.2010.024","article-title":"Electrotransfer of the full-length dog dystrophin into mouse and dystrophic dog muscles","volume":"21","author":"Pichavant","year":"2010","journal-title":"Hum Gene Ther."},{"key":"B193","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/mt.2010.23","article-title":"Expression of dog microdystrophin in mouse and dog muscles by gene therapy","volume":"18","author":"Pichavant","year":"2010","journal-title":"Mol Ther."},{"key":"B194","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1089\/hum.1998.9.5-629","article-title":"High-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscle of dystrophic dogs: prolongation of expression with immunosuppression","volume":"9","author":"Howell","year":"1998","journal-title":"Hum Gene Ther"},{"key":"B195","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/(SICI)1097-4598(199802)21:2<159::AID-MUS2>3.0.CO;2-A","article-title":"Direct dystrophin and reporter gene transfer into dog muscle in vivo","volume":"21","author":"Howell","year":"1998","journal-title":"Muscle Nerve"},{"key":"B196","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1089\/104303401750476249","article-title":"Dystrophin expression in muscle following gene transfer with a fully deleted (\u201cgutted\u201d) adenovirus is markedly improved by trans-acting adenoviral gene products","volume":"12","author":"Gilbert","year":"2001","journal-title":"Hum Gene Ther."},{"key":"B197","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1089\/hum.2018.012","article-title":"Micro-dystrophin gene therapy goes systemic in Duchenne muscular dystrophy patients","volume":"29","author":"Duan","year":"2018","journal-title":"Hum Gene Ther."},{"key":"B198","first-page":"103","article-title":"From the smallest virus to the biggest gene: marching towards gene therapy for Duchenne muscular dystrophy","volume":"6","author":"Duan","year":"2006","journal-title":"Discov Med."},{"key":"B199","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/02648725.2007.10648098","article-title":"Expending adeno-associated viral vector capacity: a tale of two vectors","volume":"24","author":"Ghosh","year":"2007","journal-title":"Biotechnol Genet Eng Rev."},{"key":"B200","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/hgtb.2015.140","article-title":"Expressing transgenes that exceed the packaging capacity of adeno-associated virus capsids","volume":"27","author":"Chamberlain","year":"2016","journal-title":"Hum Gene Ther Methods."},{"key":"B201","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1089\/humc.2015.006","article-title":"Duchenne muscular dystrophy gene therapy in the canine model","volume":"26","author":"Duan","year":"2015","journal-title":"Hum Gene Ther Clin Dev."},{"key":"B202","doi-asserted-by":"publisher","first-page":"e44438","DOI":"10.1371\/journal.pone.0044438","article-title":"Dystrophin deficiency compromises force production of the extensor carpi ulnaris muscle in the canine model of Duchenne muscular dystrophy","volume":"7","author":"Yang","year":"2012","journal-title":"PLoS ONE."},{"key":"B203","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/mt.2012.283","article-title":"Microdystrophin ameliorates muscular dystrophy in the canine model of Duchenne muscular dystrophy","volume":"21","author":"Shin","year":"2013","journal-title":"Mol Ther."},{"key":"B204","doi-asserted-by":"publisher","first-page":"5880","DOI":"10.1093\/hmg\/ddv310","article-title":"Safe and bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs with adeno-associated virus","volume":"24","author":"Yue","year":"2015","journal-title":"Hum Mol Genet."},{"key":"B205","doi-asserted-by":"publisher","first-page":"S198","DOI":"10.1016\/S1525-0016(16)33308-1","article-title":"Intravenous delivery of a novel micro-dystrophin vector prevented muscle deterioration in young adult canine Duchenne muscular dystrophy dogs","volume":"24","author":"Hakim","year":"2016","journal-title":"Mol Ther."},{"key":"B206","first-page":"192","article-title":"Single systemic AAV micro-dystrophin therapy ameliorates muscular dystrophy in young adult Duchenne muscular dystrophy dogs for up to two years","volume":"25","author":"Hakim","year":"2017","journal-title":"Mol Ther."},{"key":"B207","doi-asserted-by":"publisher","first-page":"16105","DOI":"10.1038\/ncomms16105","article-title":"Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy","volume":"8","author":"Le Guiner","year":"2017","journal-title":"Nat Commun."},{"key":"B208","first-page":"5","article-title":"AAV micro-dystrophin therapy ameliorates muscular dystrophy in young adult Duchenne muscular dystrophy dogs for up to 30 months following injection","volume":"26","author":"Hakim","year":"2018","journal-title":"Mol Ther."},{"key":"B209","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV micro-dystrophin gene therapy for duchenne muscular dystrophy","volume":"26","author":"Duan","year":"2018","journal-title":"Mol Ther."},{"key":"B210","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1089\/hum.2017.095","article-title":"Dual AAV gene therapy for Duchenne muscular dystrophy with a 7-kb mini-dystrophin gene in the canine model","volume":"29","author":"Kodippili","year":"2018","journal-title":"Hum Gene Ther."},{"key":"B211","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/76448","article-title":"In vivo targeted repair of a point mutation in the canine dystrophin gene by a chimeric RNA\/DNA oligonucleotide","volume":"18","author":"Bartlett","year":"2000","journal-title":"Nat Biotechnol."},{"key":"B212","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1126\/science.aau1549","article-title":"Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy","volume":"362","author":"Amoasii","year":"2018","journal-title":"Science."},{"key":"B213","doi-asserted-by":"publisher","first-page":"e8647","DOI":"10.1371\/journal.pone.0008647","article-title":"A Duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient cavalier king charles spaniels is amenable to exon 51 skipping","volume":"5","author":"Walmsley","year":"2010","journal-title":"PLoS ONE."},{"key":"B214","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/s41551-018-0320-0","article-title":"CRISPR alleviates muscular dystrophy in dogs","volume":"2","author":"Duan","year":"2018","journal-title":"Nat Biomed Eng."},{"key":"B215","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1089\/hum.2018.243","article-title":"Questions answered and unanswered by the first CRISPR editing study in the canine model of Duchenne muscular dystrophy","volume":"30","author":"Wasala","year":"2019","journal-title":"Hum Gene Ther."},{"key":"B216","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/ana.21627","article-title":"Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs","volume":"65","author":"Yokota","year":"2009","journal-title":"Ann Neurol."},{"key":"B217","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1073\/pnas.1613203114","article-title":"Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy","volume":"114","author":"Echigoya","year":"2017","journal-title":"Proc Natl Acad Sci USA."},{"key":"B218","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1089\/nat.2012.0368","article-title":"Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs","volume":"22","author":"Yokota","year":"2012","journal-title":"Nucleic Acid Ther."},{"key":"B219","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/mt.2011.264","article-title":"Long-term restoration of cardiac dystrophin expression in golden retriever muscular dystrophy following rAAV6-mediated exon skipping","volume":"20","author":"Bish","year":"2012","journal-title":"Mol Ther."},{"key":"B220","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1038\/mt.2012.181","article-title":"Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping","volume":"20","author":"Vulin","year":"2012","journal-title":"Mol Ther."},{"key":"B221","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/gt.2012.38","article-title":"MRI roadmap-guided transendocardial delivery of exon-skipping recombinant adeno-associated virus restores dystrophin expression in a canine model of Duchenne muscular dystrophy","volume":"20","author":"Barbash","year":"2013","journal-title":"Gene Ther."},{"key":"B222","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1038\/mt.2014.151","article-title":"Forelimb treatment in a large cohort of dystrophic dogs supports delivery of a recombinant AAV for exon skipping in Duchenne patients","volume":"22","author":"Le Guiner","year":"2014","journal-title":"Mol Ther."},{"key":"B223","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/sj.gt.3301941","article-title":"Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer","volume":"10","author":"Cerletti","year":"2003","journal-title":"Gene Ther."},{"key":"B224","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1038\/s41591-019-0594-0","article-title":"Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models","volume":"25","author":"Song","year":"2019","journal-title":"Nat Med."},{"key":"B225","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1016\/j.ymthe.2019.10.011","article-title":"Micro-utrophin therapy for Duchenne muscular dystrophy","volume":"27","author":"Duan","year":"2019","journal-title":"Mol Ther."},{"key":"B226","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1089\/hum.2011.102","article-title":"Long-term systemic myostatin inhibition via liver-targeted gene transfer in golden retriever muscular dystrophy","volume":"22","author":"Bish","year":"2011","journal-title":"Hum Gene Ther."},{"key":"B227","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13395-016-0085-7","article-title":"Dystrophin-deficient dogs with reduced myostatin have unequal muscle growth and greater joint contractures","volume":"6","author":"Kornegay","year":"2016","journal-title":"Skelet Muscle."},{"key":"B228","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1172\/JCI43844","article-title":"Mitigation of muscular dystrophy in mice by SERCA overexpression in skeletal muscle","volume":"121","author":"Goonasekera","year":"2011","journal-title":"J Clin Invest."},{"key":"B229","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/1479-5876-9-132","article-title":"SERCA2a gene transfer improves electrocardiographic performance in aged mdx mice","volume":"9","author":"Shin","year":"2011","journal-title":"J Transl Med."},{"key":"B230","first-page":"6","article-title":"AAV SERCA2a gene therapy ameliorated muscle disease in Duchenne muscular dystrophy dogs","volume":"26","author":"Kodippili","year":"2018","journal-title":"Mol Ther."},{"key":"B231","first-page":"3421","article-title":"The mucopolysaccharidosis","volume-title":"The Metabolic and Molecular Bases of Inherited Disease.","author":"Neufeld","year":"2001"},{"key":"B232","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1590\/S1415-47572010005000093","article-title":"Mucopolysaccharidosis I, II, and VI: brief review and guidelines for treatment","volume":"33","author":"Giugliani","year":"2010","journal-title":"Genet Mol Biol"},{"key":"B233","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s10545-008-0838-5","article-title":"Sanfilippo syndrome: a mini-review","volume":"31","author":"Valstar","year":"2008","journal-title":"J Inherit Metab Dis."},{"key":"B234","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1399-0004.1981.tb01821.x","article-title":"Genetic heterogeneity and clinical variability in the Sanfilippo syndrome (types A, B, and C)","volume":"20","author":"Van de Kamp","year":"1981","journal-title":"Clin Genet"},{"key":"B235","doi-asserted-by":"publisher","first-page":"e1255","DOI":"10.1542\/peds.2007-0282","article-title":"Scoring evaluation of the natural course of mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A)","volume":"120","author":"Meyer","year":"2007","journal-title":"Pediatrics"},{"key":"B236","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ymgme.2007.09.011","article-title":"Clinical and genetic spectrum of Sanfilippo type C (MPS IIIC) disease in The Netherlands","volume":"93","author":"Ruijter","year":"2008","journal-title":"Mol Genet Metab"},{"key":"B237","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/sj.ejhg.5200242","article-title":"Sanfilippo type B syndrome (mucopolysaccharidosis III B): allelic heterogeneity corresponds to the wide spectrum of clinical phenotypes","volume":"7","author":"Weber","year":"1999","journal-title":"Eur J Hum Genet."},{"key":"B238","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1750-1172-6-43","article-title":"Cognitive development in patients with Mucopolysaccharidosis type III (Sanfilippo syndrome)","volume":"6","author":"Valstar","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"B239","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s00401-007-0325-3","article-title":"Mechanisms of neurodegeneration in mucopolysaccharidoses II and IIIB: analysis of human brain tissue","volume":"115","author":"Hamano","year":"2008","journal-title":"Acta Neuropathol"},{"key":"B240","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1007\/BF00690379","article-title":"Mucopolysaccharidosis type I, II, IIIA and V","volume":"39","author":"Dekaban","year":"1977","journal-title":"Acta Neuropathol"},{"key":"B241","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1001\/archneur.1978.00500360062013","article-title":"Neuroanatomical and electroencephalographic correlations in Sanfilippo syndrome, type A","volume":"35","author":"Kriel","year":"1978","journal-title":"Arch Neurol"},{"key":"B242","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/ana.410020214","article-title":"Neuropathology of Sanfilippo syndrome","volume":"2","author":"Ghatak","year":"1977","journal-title":"Ann Neurol"},{"key":"B243","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s10545-010-9199-y","article-title":"Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype","volume":"33","author":"Valstar","year":"2010","journal-title":"J Inherit Metab Dis."},{"key":"B244","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/ajmg.c.30142","article-title":"Is Sanfilippo type B in your mind when you see adults with mental retardation and behavioral problems?","author":"Moog","year":"2007","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"B245","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1600-0447.2009.01520.x","article-title":"Sanfilippo B in an elderly female psychiatric patient: a rare but relevant diagnosis in presenile dementia. (Invited comment)","volume":"122","author":"Moog","year":"2010","journal-title":"Acta Psychiatr Scand."},{"key":"B246","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0022-3476(73)80162-3","article-title":"Beta glucuronidase deficiency: report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis","volume":"82","author":"Sly","year":"1973","journal-title":"J Pediatr."},{"key":"B247","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/gim.2017.10","article-title":"Quantitative clinical characteristics of 53 patients with MPS VII: a cross-sectional analysis","volume":"19","author":"Zielonka","year":"2017","journal-title":"Genet Med."},{"key":"B248","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1136\/jmedgenet-2015-103322","article-title":"Clinical course of sly syndrome (mucopolysaccharidosis type VII)","volume":"53","author":"Montano","year":"2016","journal-title":"J Med Genet."},{"key":"B249","doi-asserted-by":"publisher","first-page":"v4","DOI":"10.1093\/rheumatology\/ker394","article-title":"Overview of the mucopolysaccharidoses","volume":"50","author":"Muenzer","year":"2011","journal-title":"Rheumatology."},{"key":"B250","first-page":"487","article-title":"Morphologic and biochemical studies of canine mucopolysaccharidosis I","volume":"114","author":"Shull","year":"1984","journal-title":"Am J Pathol"},{"key":"B251","article-title":"Mucopolysaccharidosis in dogs and cats: clinical signs to DNA tests","volume-title":"Tufts' Canine and Feline Breeding and Genetics Conference.","author":"Wang","year":"2005"},{"key":"B252","first-page":"1802","article-title":"Corneal opacity in canine MPS I: Changes after bone marrow transplantation","volume":"30","author":"Constantopoulos","year":"1989","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B253","first-page":"677","article-title":"Long-term effects of bone marrow transplantation in dogs with mucopolysaccharidosis I","volume":"134","author":"Breider","year":"1989","journal-title":"Am J Pathol."},{"key":"B254","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1126\/scitranslmed.3001380","article-title":"Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I","volume":"2","author":"Dierenfeld","year":"2010","journal-title":"Sci Transl Med"},{"key":"B255","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/labinvest.2011.7","article-title":"Arterial pathology in canine mucopolysaccharidosis-I and response to therapy","volume":"91","author":"Lyons","year":"2011","journal-title":"Lab Invest"},{"key":"B256","first-page":"244","article-title":"Canine alpha-L-iduronidase deficiency. A model of mucopolysaccharidosis I","volume":"109","author":"Shull","year":"1982","journal-title":"Am J Pathol"},{"key":"B257","first-page":"163","article-title":"Features of brain MRI in dogs with treated and untreated mucopolysaccharidosis type I","volume":"63","author":"Vite","year":"2013","journal-title":"Comp Med"},{"key":"B258","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1203\/00006450-199807000-00012","article-title":"Sulfamidase deficiency in a family of Dachshunds: a canine model of mucopolysaccharidosis IIIA (Sanfilippo A)","volume":"44","author":"Fischer","year":"1998","journal-title":"Pediatr Res."},{"key":"B259","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1006\/geno.2002.6699","article-title":"Identification of a mutation causing mucopolysaccharidosis type IIIA in New Zealand Huntaway dogs","volume":"79","author":"Yogalingam","year":"2002","journal-title":"Genomics"},{"key":"B260","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ymgme.2014.10.008","article-title":"Development of cerebellar pathology in the canine model of mucopolysaccharidosis type IIIA (MPS IIIA)","volume":"113","author":"Hassiotis","year":"2014","journal-title":"Mol Genet Metab."},{"key":"B261","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1354\/vp.44-5-569","article-title":"Pathology of mucopolysaccharidosis IIIA in Huntaway dogs","volume":"44","author":"Jolly","year":"2007","journal-title":"Vet Pathol."},{"key":"B262","doi-asserted-by":"publisher","first-page":"e16601","DOI":"10.1371\/journal.pone.0016601","article-title":"Blood-brain barrier impairment in an animal model of MPS III B","volume":"6","author":"Garbuzova-Davis","year":"2011","journal-title":"PLoS ONE"},{"key":"B263","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1023\/A:1025177411938","article-title":"A model of mucopolysaccharidosis IIIB (Sanfilippo syndrome type IIIB): N-acetyl-alpha-D-glucosaminidase deficiency in Schipperke dogs","volume":"26","author":"Ellinwood","year":"2003","journal-title":"J Inherit Metab Dis"},{"key":"B264","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1203\/00006450-198410000-00014","article-title":"Beta-glucuronidase deficiency in a dog: a model of human mucopolysaccharidosis VII","volume":"18","author":"Haskins","year":"1984","journal-title":"Pediatr Res"},{"key":"B265","doi-asserted-by":"publisher","first-page":"e40281","DOI":"10.1371\/journal.pone.0040281","article-title":"A novel GUSB mutation in Brazilian terriers with severe skeletal abnormalities defines the disease as mucopolysaccharidosis VII","volume":"7","author":"Hytonen","year":"2012","journal-title":"PLoS ONE."},{"key":"B266","doi-asserted-by":"publisher","first-page":"532","DOI":"10.2460\/javma.2004.224.553","article-title":"Mucopolysaccharidosis type VII in a German Shepherd Dog","volume":"224","author":"Silverstein Dombrowski","year":"2004","journal-title":"J Am Vet Med Assoc"},{"key":"B267","doi-asserted-by":"publisher","first-page":"13102","DOI":"10.1073\/pnas.192353499","article-title":"Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs","volume":"99","author":"Ponder","year":"2002","journal-title":"Proc Natl Acad Sci USA."},{"key":"B268","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/sj.bmt.1702448","article-title":"Effects of bone marrow transplantation on the cardiovascular abnormalities in canine mucopolysaccharidosis VII","volume":"25","author":"Sammarco","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"B269","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1651-2227.2007.00211.x","article-title":"Animal models for mucopolysaccharidosis disorders and their clinical relevance","volume":"96","author":"Haskins","year":"2007","journal-title":"Acta Paediatr."},{"key":"B270","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1161\/01.CIR.0000138747.82487.4B","article-title":"Gene therapy ameliorates cardiovascular disease in dogs with mucopolysaccharidosis VII","volume":"110","author":"Sleeper","year":"2004","journal-title":"Circulation."},{"key":"B271","doi-asserted-by":"publisher","first-page":"43160","DOI":"10.1074\/jbc.M107778200","article-title":"Biodistribution, kinetics, and efficacy of highly phosphorylated and non-phosphorylated beta-glucuronidase in the murine model of mucopolysaccharidosis VII","volume":"276","author":"Sands","year":"2001","journal-title":"J Biol Chem."},{"key":"B272","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1089\/rej.2009.0920","article-title":"New strategies for enzyme replacement therapy for lysosomal storage diseases","volume":"13","author":"Grubb","year":"2010","journal-title":"Rejuvenation Res."},{"key":"B273","doi-asserted-by":"publisher","first-page":"15172","DOI":"10.1073\/pnas.0607053103","article-title":"Enzyme therapy in mannose receptor-null mucopolysaccharidosis VII mice defines roles for the mannose 6-phosphate and mannose receptors","volume":"103","author":"Sly","year":"2006","journal-title":"Proc Natl Acad Sci USA."},{"key":"B274","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1006\/bmme.1996.0044","article-title":"Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I","volume":"58","author":"Kakkis","year":"1996","journal-title":"Biochem Mol Med."},{"key":"B275","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ymgme.2017.10.007","article-title":"Treatment of brain disease in the mucopolysaccharidoses","author":"Scarpa","year":"2017","journal-title":"Mol Genet Metab"},{"key":"B276","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.ymgme.2014.05.015","article-title":"Intra-articular enzyme replacement therapy with rhIDUA is safe, well-tolerated, and reduces articular GAG storage in the canine model of mucopolysaccharidosis type I","volume":"112","author":"Wang","year":"2014","journal-title":"Mol Genet Metab."},{"key":"B277","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ymgme.2010.06.020","article-title":"Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type I","volume":"101","author":"Dickson","year":"2010","journal-title":"Mol Genet Metab."},{"key":"B278","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.expneurol.2014.09.008","article-title":"Delivery of therapeutic protein for prevention of neurodegenerative changes: comparison of different CSF-delivery methods","volume":"263","author":"Marshall","year":"2015","journal-title":"Exp Neurol."},{"key":"B279","doi-asserted-by":"publisher","first-page":"e30341","DOI":"10.1371\/journal.pone.0030341","article-title":"CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder","volume":"7","author":"Calias","year":"2012","journal-title":"PLoS ONE."},{"key":"B280","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s10545-016-9994-1","article-title":"Slow, continuous enzyme replacement via spinal CSF in dogs with the paediatric-onset neurodegenerative disease, MPS IIIA","volume":"40","author":"King","year":"2017","journal-title":"J Inherit Metab Dis."},{"key":"B281","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ymgme.2004.07.003","article-title":"Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I","volume":"83","author":"Kakkis","year":"2004","journal-title":"Mol Genet Metab"},{"key":"B282","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ymgme.2006.12.012","article-title":"Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid","volume":"91","author":"Dickson","year":"2007","journal-title":"Mol Genet Metab"},{"key":"B283","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ymgme.2009.07.013","article-title":"Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs\u2013a proof of principle study","volume":"98","author":"Hemsley","year":"2009","journal-title":"Mol Genet Metab."},{"key":"B284","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.nbd.2011.04.014","article-title":"Enzyme replacement reduces neuropathology in MPS IIIA dogs","volume":"43","author":"Crawley","year":"2011","journal-title":"Neurobiol Dis."},{"key":"B285","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ymgme.2013.03.013","article-title":"The effect of neonatal gene therapy on skeletal manifestations in mucopolysaccharidosis VII dogs after a decade","volume":"109","author":"Xing","year":"2013","journal-title":"Mol Genet Metab."},{"key":"B286","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/mt.2010.265","article-title":"Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes","volume":"19","author":"Ellinwood","year":"2011","journal-title":"Mol Ther."},{"key":"B287","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ymgme.2016.06.006","article-title":"Neonatal tolerance induction enables accurate evaluation of gene therapy for MPS I in a canine model","volume":"119","author":"Hinderer","year":"2016","journal-title":"Mol Genet Metab."},{"key":"B288","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/mt.2015.189","article-title":"Evaluation of AAV-mediated gene therapy for central nervous system disease in canine mucopolysaccharidosis VII","volume":"24","author":"Gurda","year":"2016","journal-title":"Mol Ther."},{"key":"B289","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ymgme.2013.11.015","article-title":"Early initiation of enzyme replacement therapy for the mucopolysaccharidoses","volume":"111","author":"Muenzer","year":"2014","journal-title":"Mol Genet Metab."},{"key":"B290","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1056\/NEJM200101183440304","article-title":"Enzyme-replacement therapy in mucopolysaccharidosis I","volume":"344","author":"Kakkis","year":"2001","journal-title":"N Engl J Med."},{"key":"B291","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ymgme.2006.08.007","article-title":"A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years","volume":"90","author":"Sifuentes","year":"2007","journal-title":"Mol Genet Metab."},{"key":"B292","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1590\/S1415-47572014000100006","article-title":"Enzyme replacement therapy for Mucopolysaccharidosis Type I among patients followed within the MPS Brazil Network","volume":"37","author":"Dornelles","year":"2014","journal-title":"Genet Mol Biol."},{"key":"B293","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00431-011-1606-3","article-title":"The role of enzyme replacement therapy in severe Hunter syndrome-an expert panel consensus","volume":"171","author":"Muenzer","year":"2012","journal-title":"Eur J Pediatr."},{"key":"B294","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ymgme.2016.05.006","article-title":"A phase 1\/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA","volume":"118","author":"Jones","year":"2016","journal-title":"Mol Genet Metab."},{"key":"B295","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0022-3476(69)80464-6","article-title":"Fucosidosis","volume":"75","author":"Durand","year":"1969","journal-title":"J Pediatr"},{"key":"B296","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/ajmg.1320380125","article-title":"Fucosidosis revisited: a review of 77 patients","volume":"38","author":"Willems","year":"1991","journal-title":"Am J Med Genet"},{"key":"B297","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/BF01799172","article-title":"Evolution of the neuroimaging changes in fucosidosis type II","volume":"19","author":"Terespolsky","year":"1996","journal-title":"J Inherit Metab Dis"},{"key":"B298","first-page":"809","article-title":"Neuroradiologic findings in fucosidosis, a rare lysosomal storage disease","volume":"16","author":"Provenzale","year":"1995","journal-title":"AJNR Am J Neuroradiol"},{"key":"B299","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1097\/00005072-199909000-00001","article-title":"Abnormalities of developing white matter in lysosomal storage diseases","volume":"58","author":"Folkerth","year":"1999","journal-title":"J Neuropathol Exp Neurol"},{"key":"B300","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1055\/s-2008-1077048","article-title":"Severe hypomyelination as the leading neuroradiological sign in a patient with fucosidosis","volume":"39","author":"Prietsch","year":"2008","journal-title":"Neuropediatr"},{"key":"B301","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1093\/brain\/awq257","article-title":"Magnetic resonance imaging pattern recognition in hypomyelinating disorders","volume":"133","author":"Steenweg","year":"2010","journal-title":"Brain"},{"key":"B302","first-page":"153","article-title":"Allogenic bone marrow transplantation in fucosidosis","volume":"15","author":"Vellodi","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"B303","first-page":"756","article-title":"Identification of a mutation in the structural alpha-L-fucosidase gene in fucosidosis","volume":"43","author":"Willems","year":"1988","journal-title":"Am J Hum Genet"},{"key":"B304","first-page":"89","article-title":"The clinical effects of lysosomal enzyme replacement by bone marrow transplantation after total lymphoid irradiation on neurologic disease in fucosidase deficient dogs","volume":"20","author":"Taylor","year":"1988","journal-title":"Transplant Proc"},{"key":"B305","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/BF00690639","article-title":"A suspected new canine storage disease","volume":"56","author":"Hartley","year":"1982","journal-title":"Acta Neuropathol"},{"key":"B306","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1748-5827.1987.tb03883.x","article-title":"Canine fucosidosis: clinical findings","volume":"28","author":"Taylor","year":"1987","journal-title":"J Small Anim Pract"},{"key":"B307","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/NEN.0000000000000075","article-title":"Oligodendrocyte loss during the disease course in a canine model of the lysosomal storage disease fucosidosis","volume":"73","author":"Fletcher","year":"2014","journal-title":"J Neuropathol Exp Neurol"},{"key":"B308","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1136\/jmg.33.4.284","article-title":"The molecular defect underlying canine fucosidosis","volume":"33","author":"Skelly","year":"1996","journal-title":"J Med Genet"},{"key":"B309","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1159\/000322541","article-title":"Canine fucosidosis: a neuroprogressive disorder","volume":"8","author":"Kondagari","year":"2011","journal-title":"Neurodegener Dis"},{"key":"B310","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/ajmg.1320420439","article-title":"Amelioration of clinical disease following bone marrow transplantation in fucosidase-deficient dogs","volume":"42","author":"Taylor","year":"1992","journal-title":"Am J Med Genet"},{"key":"B311","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.expneurol.2011.04.019","article-title":"Treatment of canine fucosidosis by intracisternal enzyme infusion","volume":"230","author":"Kondagari","year":"2011","journal-title":"Exp Neurol"},{"key":"B312","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13023-015-0357-z","article-title":"The effects of intracisternal enzyme replacement versus sham treatment on central neuropathology in preclinical canine fucosidosis","volume":"10","author":"Kondagari","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"B313","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/sj.bmt.1702994","article-title":"Four year follow-up of a case of fucosidosis treated with unrelated donor bone marrow transplantation","volume":"27","author":"Miano","year":"2001","journal-title":"Bone Marrow Transplant"}],"container-title":["Frontiers in Veterinary Science"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fvets.2020.00080\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T23:18:32Z","timestamp":1722554312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fvets.2020.00080\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,11]]},"references-count":313,"alternative-id":["10.3389\/fvets.2020.00080"],"URL":"https:\/\/doi.org\/10.3389\/fvets.2020.00080","relation":{},"ISSN":["2297-1769"],"issn-type":[{"value":"2297-1769","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,11]]},"article-number":"80"}}